Corporate
News Releases
2024 September
Pharmaceuticals
HemeSight®, the First-in-Japan Comprehensive Genomic Profiling Assay for Hematological Malignancies, Receives Its First Regulatory Approval - HemeSight® hematological malignancies gene panel test approved in Japan -
Corporate
Heartful Kawauchi ReceivedJapan Organization for Employment of the Elderly, Persons with Disabilities and Job Seekers President's Award
Nutraceuticals
Otsuka Pharmaceutical Advancing Women's Health Business Bonafide Health Launched "Thermella", a Plant-derived Supplement to Support Menopausal Women in the U.S.
Pharmaceuticals
Otsuka Obtains Additional Indication for Rexulti®in Japan as an Adjunctive Treatment for Agitation Associated with Dementia due to Alzheimer's Disease
Pharmaceuticals
Otsuka Receives Approval in Japan for Lupkynis® as a Treatment for Lupus Nephritis
Pharmaceuticals
Otsuka Pharmaceutical Completes Acquisition of Jnana Therapeutics Inc.
Pharmaceuticals
Otsuka to Participate in the Orange Innovation Project, Promoted by Japan's Ministry of Economy, Trade and Industry
Corporate
Otsuka Pharmaceutical Launches Corporate Health Support Program "fitbiz"Supporting Employees in Building and Maintaining Healthy Habits
Nutraceuticals
Otsuka Pharmaceutical signs global supporter agreement with World AthleticsSponsorship will cover the World Athletics Championships Tokyo 25POCARI SWEAT will support the event with the key message "Believe In Your Potential."
Pharmaceuticals
Otsuka and Jolly Good Launch FACEDUO Dementia Care Support VR
Nutraceuticals
New from the Skincare Brand sakuraé Introducing Sakuraé Clear Cycle Lotion for Translucent and Healthy Skin
Nutraceuticals
U.S. Originated Nutrition Tracking Service "Vivoo" Launches in Japan Providing Easy Access to Nutritional Data to Support Healthy Lifestyles
2024 August
Pharmaceuticals
Otsuka Precision Health and Click Therapeutics Announce Launch of Rejoyn™, the First-And-Only Prescription Digital Therapeutic Cleared by the FDA for the Adjunctive Treatment of Major Depressive Disorder (MDD) Symptoms ーRejoyn, a first-of-its-kind digital treatment designed to help with cognitive control of emotion, is now available in mobile app stores and can be unlocked with a prescription from a healthcare providerー
Corporate
Otsuka Pharmaceutical Joins Project to Promote Use of Sustainable Aviation Fuel in Air Cargo TransportationーOperated by Tokyo Metropolitan Government, Aiming for a Decarbonized Societyー
Pharmaceuticals
Otsuka and Lundbeck Present New REXULTI® (brexpiprazole) Post Hoc Efficacy Data Analyses for Agitation Associated with Dementia Due to Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2024
Corporate
Otsuka Pharmaceutical to Acquire Jnana Therapeutics Inc. - Transaction Includes JNT-517, a Potential First-In-Class Oral Treatment for Phenylketonuria (PKU) - - Expands Specialty and Autoimmune Portfolios and Drug Discovery Technologies -
2024 July
2024 June
Pharmaceuticals
Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD)
Nutraceuticals
Introducing a New Calorie Mate Block Production LineDeveloping a Sustainable Factory that is Kind to the Environment and Employees
Pharmaceuticals
Otsuka Concludes Expanded Licensing Agreement for Donidalorsen in Hereditary Angioedema, Expanding its Development and Sales Area to Asia Pacific including Japan
Nutraceuticals
Korea Otsuka Pharmaceutical Launches Soy Bar "SOYJOY"Introducing a New Concept of Healthy Snacking
2024 May
Corporate
Otsuka Pharmaceutical and Taiho PharmaceuticalCommence Material Recycling of Waste PTP Used in Pharmaceutical Packaging
Nutraceuticals
InnerSignal Introduces a New Basic Skincare Line Launch of "Repair Lotion" and "Repair Milk" to Address Epidermal Imbalance
Pharmaceuticals
Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults
Pharmaceuticals
Otsuka to Terminate Development of AVP-786
Pharmaceuticals
Novartis launches Entresto® Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients
Pharmaceuticals
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment of Hypercholesterolemia
Nutraceuticals
Carbonated Nutritional Drink "ORONAMIN C DRINK" Debuts in Egypt
2024 April
Pharmaceuticals
Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD
Pharmaceuticals
Otsuka Works with Verily to Launch Longitudinal Mental Health Registry to Advance Novel Research in Psychiatry in the U.S.
Pharmaceuticals
FACEDUO Emotion Recognition Training VR now available - Support for those with developmental conditions such as autism spectrum disorder (ASD), which makes it difficult to read emotions -
Pharmaceuticals
U.S. Food and Drug Administration (FDA) Clearance of Rejoyn® First Prescription Digital Therapeutic Authorized in the U.S. for the Adjunctive Treatment of Major Depressive Disorder (MDD) symptoms
2024 March
Pharmaceuticals
Submission of an Application for the First Hematological Malignancies Gene Panel Test in Japan
Pharmaceuticals
Abilify Maintena® 960mg (aripiprazole) approved in the EU as the first once-every-two-months long-acting injectable for the maintenance treatment of schizophrenia
Pharmaceuticals
Novartis receives approval in Japan for Entresto® Granular Tablets for Pediatric Use, a formulation dedicated for pediatric patients with chronic heart failure
Pharmaceuticals
Otsuka Pharmaceutical's subsidiaries in Indonesia awarded Exemplar Award by Ending Workplace Tuberculosis (EWTB) for Otsuka's efforts to eliminate tuberculosis
Pharmaceuticals
Otsuka Announces Interim Data from Phase 2b/c Trial Indicating New Investigational Compound May Shorten Tuberculosis Treatment
Pharmaceuticals
Otsuka and Lundbeck Presented New Data Analyses on the Efficacy of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer's Disease
Corporate
Otsuka Pharmaceutical Enters into Cooperation Agreement on Heat Illness Prevention with Environmental Restoration and Conservation Agency
Pharmaceuticals
Otsuka and Sumitomo Revise License Agreement - Otsuka holds exclusive rights to develop, manufacture, and commercialize ulotaront and SEP-380135 worldwide -
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 70.1 KB)
Nutraceuticals
New SOYJOY Fig & Raisin A Whole-Soy Nutrition Bar Enhanced with Flavorful Figs
2024 February
Pharmaceuticals
Otsuka Enters into Investment Contract with AN Venture Partners
Nutraceuticals
Otsuka Sponsors TOKYO MARATHON 2024 POCARI SWEAT Supports Runners Achieve Their Goals
Nutraceuticals
Launch of AR-Based Nutrition Education Game App, "Mogumogu Town"Collect "Mogumin" Food Characters and Build Your Town
Pharmaceuticals
Sibeprenlimab Received U.S. FDA Breakthrough Therapy Designation for the Treatment of Immunoglobulin A Nephropathy (IgAN)
Corporate
Otsuka Pharmaceutical Launches "Kenkokeiei Tsunagaru Support ONLINE"Broadening Support for Resolving Corporate Health Challenges
Pharmaceuticals
Otsuka Announces Phase 3 Topline Results of AVP-786 in the Treatment of Agitation Associated with Dementia due to Alzheimer's Disease
Pharmaceuticals
Novartis Obtains Approval for Additional Indication of Pediatric Chronic Heart Failure for Angiotensin Receptor Neprilysin Inhibitor (ARNI) Entresto® Tablet = Novartis and Otsuka to provide information to healthcare professionals on additional indication for Entresto =
Pharmaceuticals
Otsuka and Jolly Good to Start Delivery of FACEDUO Content for Family Support of People with Severe Social Withdrawal (Hikikomori) FACEDUO is a virtual reality program for social skills training support
Corporate
Otsuka Group Selected for CDP Climate Change A List for a Second Consecutive Year
2023 December
Pharmaceuticals
Otsuka Obtains the Additional Indication of Adjunctive Treatment of Major Depressive Disorder for Rexulti® in Japan
Pharmaceuticals
Otsuka and Ionis Enter into Licensing Agreement Covering Europe for Donidalorsen in Hereditary Angioedema
Corporate
Otsuka Pharmaceutical Introduces New "Self-Care Leave" System
Corporate
D&I Award 2023 - Otsuka Pharmaceutical Designated as "Best Workplace"
Nutraceuticals
Pharmavite, a U.S. subsidiary of Otsuka Pharmaceutical, acquires Bonafide Health, a provider of women's health products
2023 November
Corporate
Otsuka Pharmaceutical to Sponsor Thematic Project "Resonance of Lives" at the Expo 2025 Osaka, Kansai, Japan
Pharmaceuticals
Otsuka's U.K. subsidiary Astex Has Third Approval Success in a Drug Discovery Collaboration - AstraZeneca's Truqap™ for the treatment of metastatic breast cancer approved in the U.S.
Pharmaceuticals
Otsuka Submits New Drug Application in Japan for Voclosporin in the Treatment of Patients with Lupus Nephritis
Pharmaceuticals
MIREVO®, a New Cognitive Function Testing Application for Dementia Care Support, Obtains Regulatory Approval, a First in Japan
Nutraceuticals
Selected as METI's "Model Project for the Promotion of PHR Services" Launch of a Healthcare Service that Improves Health without Conscious Effort
Corporate
Otsuka Pharmaceutical Granted Silver Certification in PRIDE Index 2023 for LGBTQ+ Initiatives
Corporate
Otsuka Announces Personnel Changes
Pharmaceuticals
New England Journal of Medicine Publishes Complete Results of Positive Phase 2 Trial of Sibeprenlimab in Treatment of Immunoglobulin A Nephropathy (IgAN)
2023 October
Pharmaceuticals
Otsuka Applies in Japan for the Additional Indication for Agitation Associated with Dementia due to Alzheimer's Disease for Rexulti® (brexpiprazole)
Corporate
Otsuka Pharmaceutical Receives Eruboshi Grade 3 Certification as an Excellent Company Under the Act on Promotion of Women's Participation and Advancement in the Workplace
Pharmaceuticals
Otsuka Pharmaceutical Announces Positive Topline Results from Two Pivotal Phase 3 Trials of Centanafadine as a Treatment for Adolescents and Children with Attention-Deficit/Hyperactivity Disorder (ADHD)
Nutraceuticals
First PET Bottle and Paper Cup Recycling Initiatives for Tokyo Legacy Half Marathon
Nutraceuticals
Introducing InnerSignal SC Rich Cream- Regulates moisture in the stratum corneum for a higher level of skin care experience -
2023 September
Pharmaceuticals
Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia
Corporate
Otsuka Pharmaceutical Enters into Cooperative Agreement with Japan Association of Public Mental Health & Welfare Workers
Pharmaceuticals
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
Pharmaceuticals
Otsuka Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults
Pharmaceuticals
Otsuka Pharmaceutical to Acquire Mindset Pharma - Strengthens pipeline in the area of psychiatric and neurological disorders -
2023 August
Corporate
Otsuka Pharmaceutical Participates in Summer Events in Tokushima, Japan -EXCITING SUMMER in WAJIKI and ORONAMIN C DRINK PRESENTS Awa Odori Sound Festival-
Pharmaceuticals
Astex Expands Drug Discovery Collaboration With MSD
Nutraceuticals
POCARI SWEAT X TOKUSHIMA VORTIS Football Dream Project Phase 3Otsuka Pharmaceutical and Tokushima Vortis collaborate in exchange program for junior football players in Cambodia
2023 July
Nutraceuticals
Launch of TCRP NEXT, a New Collaboration Aiming to Promote Total Conditioning- Enhancing sustainable international competitiveness and transitioning from high performance to life performance -
Pharmaceuticals
Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia
Corporate
Tokushima Prefecture Signs First Resource Circulation Agreement with Otsuka Pharmaceutical- Promotion of Horizontal PET Bottle Recycling Initiatives -
Nutraceuticals
Otsuka Pharmaceutical Enters into Cooperative Agreementwith Ministry of the Environment
2023 April
Pharmaceuticals
FDA Approves Otsuka and Lundbeck's ABILIFY ASIMTUFII®(aripiprazole), the First, Two-month, Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
Pharmaceuticals
Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on brexpiprazole for the Treatment of Agitation Associated with Alzheimer's Dementia
2023 March
Corporate
Otsuka Holdings Selected as Nadeshiko Brand for FY 2022
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 58.6 KB)
Nutraceuticals
New SOYJOY Fruits & Cheese Baked cheesecake-flavored whole-soy nutrition bar with ample fruit
Nutraceuticals
Introducing New UL•OS Scalp Shampoo Volume-up Addresses men's scalp condition and hair problems
Nutraceuticals
New EQUELLE gelée , an Extension of the EQUELLE BrandA convenient, smart solution for midlife transitions
2023 February
Nutraceuticals
Otsuka Pharmaceutical an Official Partner of Tokyo Marathon 2023Providing health management support for runners and officials
Corporate
Otsuka Pharmaceutical Finalizes Agreement with Naruto City and Toyota Tsusho Corporation to Promote Horizontal Recycling of PET bottles
Corporate
Otsuka Pharmaceutical Receives "Consumer-oriented Activity Award" at the 8th ACAP Consumer-oriented Activity Awards - Recognized for ongoing women’s health-care initiatives-
2023 January
Corporate
Otsuka Pharmaceutical Installs Solar Power Generation Systems at Takasaki and Tokushima Itano Factories-Targeting reduction of CO2 emissions-
Pharmaceuticals
Otsuka Applies for the Additional Indication of Adjunctive Treatmentof Major Depressive Disorder for Rexulti® (brexpiprazole) in Japan
Pharmaceuticals
Otsuka and Schrödinger Announce Single-Target, Drug Discovery Collaboration in Neurology
Pharmaceuticals
Otsuka and Lundbeck announce FDA acceptance and priority review of sNDA for brexpiprazole for the treatment of agitation associated with Alzheimer's dementia
2022 December
2022 November
Nutraceuticals
New skin care brand Introducing Sakuraé Double Action Serum - Japan's first "double brightening" effect -
Nutraceuticals
Otsuka Pharmaceutical Finalizes Business Collaboration Agreement for Horizontal Recycling of PET Bottles
Nutraceuticals
Favorable Decision of the Supreme Court on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol
Pharmaceuticals
Otsuka Announces the Launch in Japan of Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225mg for Preventive Treatment of Migraine
Pharmaceuticals
Announcement of Termination of Co-Development and Exclusive MarketingAgreements with Takara Bio for NY-ESO-1・siTCR® gene therapy candidate
Corporate
Otsuka Opens Osaka Research Center for Drug Discovery in Osaka Prefecture, Japan
2022 October
Pharmaceuticals
Avanir Pharmaceuticals, Inc. Business Will Be IntegratedInto Otsuka America Pharmaceuticals, Inc. as of January 1, 2023
Nutraceuticals
Otsuka Pharmaceutical Supports Tokyo Legacy Half Marathon 2022Helping runners to complete the distance and set new records
Pharmaceuticals
Otsuka and Jolly Good to Launch FACEDUO, a Virtual Reality Support Program forPatients with Schizophrenia and Their Supporters
Nutraceuticals
Announcement of Price Revisions for Applicable Products
2022 September
Pharmaceuticals
Otsuka to Launch QuickNaviTM-Noro3, a Norovirus Antigen Quick Detection Kit - Minimum detection sensitivity improved compared to QuickNaviTM-Noro2 -
Nutraceuticals
Launch of OTSUKA BLUE PLANET in IndonesiaSustainability Program Aims to Contribute to Local Environmental Efforts
Pharmaceuticals
Otsuka announces EC approval of Lupkynis® (voclosporin) as first oral treatment for active lupus nephritis
Nutraceuticals
Launch of SOYJOY Sweet PotatoPopular ingredient flavors new whole-soy nutrition bar
Pharmaceuticals
Otsuka and Lundbeck Announce U.S. FDA Acceptance of New Drug Application forAripiprazole 2-month, Ready-to-Use, Long-acting Injectable to Treat Schizophrenia andBipolar I Disorder in Adults
Pharmaceuticals
Otsuka Pharmaceutical announces positive results of phase III trial in Japan for brexpiprazole in the treatment of major depressive disorder
Pharmaceuticals
Otsuka Measurement Kit to be Covered by National Health Insurance in Japan forPhiladelphia-Chromosome-Positive, Acute Lymphoblastic Leukemia
2022 August
Nutraceuticals
Otsuka Subsidiaries Become Official Supporters of ASEAN Football Federation ChampionshipContributing to Safe Tournament Management and Optimum Conditioning for Players and Staf
Nutraceuticals
Announcement of Price Revisions for Applicable Products
Pharmaceuticals
European Medicines Agency commences review of oral fixed-dosecombination of decitabine and cedazuridine for the treatment ofadults with acute myeloid leukemia
Pharmaceuticals
PAN-TB Collaboration to Advance Investigational Tuberculosis Drug Regimens to Phase 2 Clinical Trials
Nutraceuticals
Presentation of Research Regarding Compounds Contributing to Alleviation of Premenstrual Symptoms
Pharmaceuticals
Otsuka Pharmaceutical and Lundbeck present positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole at the 2022 Alzheimer's Association International Conference
2022 July
Pharmaceuticals
Otsuka receives positive CHMP opinion for LupkynisTM (voclosporin)for the treatment of active lupus nephritis
Nutraceuticals
Introducing New B240 TabletsEffortless way to consume a unique ingredient for maintenance of physical condition
Corporate
Full-scale Launch of "Kenkokeiei Tsunagaru Support" ServiceOtsuka Pharmaceutical Supports Resolution of Health Issues for Small & Medium-sized Enterprises
2022 June
Nutraceuticals
POCARI SWEAT 250ml Returnable Bottle For Distribution via Circular Shopping Platform 'Loop'
Pharmaceuticals
Otsuka Pharmaceutical and Lundbeck announce positive results showing reduced agitation in patients with Alzheimer's dementia treated with brexpiprazole
Pharmaceuticals
European Medicines Agency Commences Review of Aripiprazole2-Month Long-Acting Injectable for the Maintenance Treatment of Schizophrenia in Adult Patients Stabilised with Aripiprazole
Pharmaceuticals
Otsuka Obtains Approval in Japan for Auto-Injector Dosage Form for AJOVY® Subcutaneous Injection 225 mg for Preventive Treatment of Migraine
Pharmaceuticals
Otsuka Enters Collaboration with xFOREST Therapeutics on RNA Structure- Targeted Drug Discovery Covering Multiple Diseases
Nutraceuticals
Otsuka Pharmaceutical Publishes Paper Investigating Binding Property of Salivary IgA on Pathogenic Microorganisms
Pharmaceuticals
Launch in Japan of Moizerto® Ointment, a Treatment for Atopic Dermatitis
2022 May
Nutraceuticals
POCARI SWEAT × TOKUSHIMA VORTIS Football Dream ProjectOtsuka and Tokushima Vortis collaborate to support overseas promotion of health through sports activities and regional vitalization in Tokushima
Pharmaceuticals
Launch in Japan of SAMTASU® for IV Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Pharmaceuticals
Announcement of Termination of Global License Agreements for Renal Anemia Treatment with Akebia Therapeutics, Inc.
Corporate
Four Otsuka Group Companies in Indonesia Adopts CO2-Free Electricity - Approximately 13% reduction in annual CO2 emissions -
2022 April
Pharmaceuticals
Otsuka and Ai-BrainScience Announce Sales Collaboration Agreement for New Cognitive Function Testing Application That Uses Eye Tracking Technology
Corporate
Otsuka Group Joins RE100 International Initiative - Committed to 100% Renewable Energy -
Pharmaceuticals
Osaka University and Otsuka Pharmaceutical to Enter into an Exclusive License Agreement on New Anti-tumor Antibody
2022 March
Pharmaceuticals
Akebia Therapeutics Receives Complete Response Letter from U.S. FDAfor Vadadustat for the Treatment of Anemia associated with Chronic Kidney Diseasein Adult Patients
Pharmaceuticals
Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. ofRadioligand Therapy for Metastatic Castration-Resistant Prostate Cancer- Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceutical -
Pharmaceuticals
Otsuka Obtains Approval in Japan for SAMTASU® for I.V. Infusion, a V2 -Receptor Antagonist for the Treatment of Cardiac Edema
Corporate
Packaging for a Sustainable FuturePOCARI SWEAT to Introduce Recycled PET for Bottles from Spring 2022
Corporate
Otsuka Pharmaceutical Appointments of Board Members and Statutory Auditors (PDF: 58.8 KB)
Nutraceuticals
～Otsuka Pharmaceutical Survey of "Working Women's Health Consciousness"～ Indication that women’s health concerns (PMS, menopause) significantly affect career paths. Need for recognition as "corporate issues" beyond individual efforts.
Nutraceuticals
Introducing New Calorie Mate BLOCK VanillaNutritional Balance in Everyday Life for People of All Ages
2022 February
Nutraceuticals
Otsuka Extends Its Deep Expertise in Soy-Based Products to Launch SOYJOY 100% Plant-Based Series
Corporate
Favorable Judgment on Lawsuit on Patent Right Held in Relation to Otsuka Pharmaceutical Foods Containing Equol
Corporate
Otsuka Pharmaceutical Certified as Sports Yell Company for 5th Consecutive Year- Collaboration among Otsuka Group Companies to Support Employees' Ongoing Fitness Efforts -
2022 January
Pharmaceuticals
Otsuka Enters Agreement with Jolly Good for Co-Development and Sales Rights in Japanfor a Social Skills Training Platform Using Virtual Reality in the Psychiatric Field
Corporate
Favorable judgment on lawsuit for revocation of trial decision on patent right held in relation to equol-containing foods
Pharmaceuticals